Adrenocortical carcinoma is a rare disease type with a limited number of available preclinical models for the development of novel therapeutics. CrownBio’s adrenal cancer tumor homografts preserve organ-specific and disease-relevant mutations such as TP53 and Ptch1 loss, making them the ideal preclinical platform for adrenal cancer in vivo drug development.